Surrozen, Inc./DE Cash and Restricted Cash
Surrozen, Inc./DE (SRZN) had Cash and Restricted Cash of $102.67 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $102.67M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $107.60M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $89.93M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $82.02M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents as first filed |
|---|---|---|
| 2026-06-30 | $102.67M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $107.60M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $89.93M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $82.02M 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $91.08M 10-Q · filed 2026-08-06 | |
| 2025-03-31 | $102.33M 10-Q · filed 2026-05-06 | |
| 2024-12-31 | $35.25M 10-Q · filed 2026-08-06 | |
| 2024-09-30 | $31.70M 10-Q · filed 2025-11-07 | |
| 2024-06-30 | $38.45M 10-Q · filed 2025-08-08 | |
| 2024-03-31 | $27.98M 10-Q · filed 2025-05-09 | |
| 2023-12-31 | $36.73M 10-K · filed 2026-03-23 | |
| 2023-09-30 | $34.40M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $36.90M 10-Q · filed 2024-08-12 | |
| 2023-03-31 | $28.21M 10-Q · filed 2024-05-08 | |
| 2022-12-31 | $25.09M 10-K · filed 2025-03-31 | |
| 2022-09-30 | $25.94M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $17.27M 10-Q · filed 2023-08-09 | |
| 2022-03-31 | $14.71M 10-Q · filed 2023-05-10 | |
| 2021-12-31 | $33.50M 10-K · filed 2024-04-10 | |
| 2021-09-30 | $61.50M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $19.25M 10-Q · filed 2022-08-11 | $390.67K 10-Q · filed 2021-08-09 |
| 2021-03-31 | $23.81M 10-Q · filed 2022-05-11 | $774.93K 10-Q · filed 2021-05-24 |
| 2020-12-31 | $35.39M 10-K · filed 2023-03-31 | $987.19K 10-K · filed 2021-03-31 |
| 2020-09-30 | $59.33M 10-Q · filed 2021-11-15 | $0.00 10-Q/A · filed 2021-01-05 |
| 2019-12-31 | $29.51M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |